May 19, 2020
A health ministry committee will discuss whether to grant orphan status for five "regenerative medicine" products including Otsuka Pharmaceutical’s gene therapy TBI-1301 for the treatment of synovial sarcoma, which has been designated for the sakigake fast-track review pathway. The discussion...read more